Drug Trial Radar · NCT04969315
TT-4 and TT-10 as Single Agents and in Combination in Subjects With Advanced Selected Solid Tumors and Pleural Mesothelioma
Last checked: Nov 19, 2026Latest source record: Sep 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
35
Planned (sponsor's estimate)
Start
Jun 23, 2023
Primary completion
Dec 1, 2028
Study completion Mar 1, 2029
Sponsor
- Lead sponsor
- Portage BiotechIndustry
- Sponsor type
- Industry
- First posted
- Jul 20, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to evaluate TT-10, TT-4 and TT-10 + TT-4, (Dual Blockade) in participants with advanced selected solid tumors, who have failed or are not eligible for standard of care. The main questions it aims to answer are: 1. To evaluate the safety and tolerability of TT-10, TT-4 Diacid, and combination therapy (TT-10 + TT-4 Diacid). 2. To determine the maximum tolerated dose (MTD) or phase 2 recommended dose of TT-10, TT-4 Diacid, and combination therapy (TT-10 + TT-4 Diacid). 3. To evaluate safety of combination therapy (TT-10 + TT-4 Diacid).
Conditions
- Renal Cell Cancer
- Castrate Resistant Prostate Cancer
- Non Small Cell Lung Cancer
- Pleural Mesothelioma Malignant
Interventions
TT-10Drug
TT-10 orally administered BID
TT-4Drug
TT-4 is orally administered QD
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of subjects with Dose Limiting Toxicities (DLTs) of TT-10, TT-4 and TT-10 + TT-4 during the dose escalation phaseTime frame: 28 Days
- Define the maximum tolerated dose (MTD) or phase 2 recommended dose of TT-10, TT-4 and TT-10 + TT-4 during the dose escalation phaseTime frame: Through study completion, an average of 1 year
- Expansion cohort primary objective - safetyTime frame: Through study completion, an average of 1 year
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
USC Norris Comprehensive Cancer Center
Los Angeles, California · Recruiting
The University of Texas MD Anderson Cancer Center
Houston, Texas · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.